Drugs / Stapokibatrt
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07106372 | Sep 2025 → Feb 2027 expected | atopic eczema | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06956196 | May 2025 → May 2026 overdue | atopic eczema | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stapokibatrt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07106372 ↗ |
| Route | Subcutaneous | “Subcutaneous injection(SC)” NCT06956196 ↗ |